Harmonic Discovery, a New York-based therapeutics company building an integrated computational and experimental platform for kinase drug discovery and targeted polypharmacology, announced its launch with $8 million in seed funding.
The funding round was led by Innovation Endeavors, with participation from Fifty Years, Y Combinator, Boom Capital, and Caffeinated Capital.
With this new funding, Harmonic Discovery plans to advance its drug discovery platform and pipeline by expanding its leadership team, building proprietary chemical libraries, and scaling its laboratory operations.
"There is an enormous opportunity to create safer and more effective drugs. We passionately believe that our unified approach to kinase drug discovery will be the first step in unlocking completely new ways to treat diseases. We're thrilled to have Joel and the team at Innovation Endeavors on board to help us embrace our vision for the future of therapeutics,"-Rayees Rahman, PhD., CEO, and Co-Founder of Harmonic Discovery, said.
Harmonic Discovery is a resident of JLABS @ NYC, part of Johnson & Johnson Innovation's global network of life science incubators.
Company: Harmonic Discovery Inc.
Round: Seed Round
Funding Month: September 2022
Lead Investors: Innovation Endeavors
Additional Investors: Fifty Years, Y Combinator, Boom Capital, and Caffeinated Capital
Company Website: https://www.harmonicdiscovery.com/
Software Category: Computational and Experimental platform
About the Company: Harmonic Discovery is a therapeutics company building an integrated computational and experimental platform for kinase drug discovery and targeted polypharmacology. Harmonic Discovery uses a machine learning platform to facilitate drug discovery. The platform combines several aspects of traditional discovery, such as examining the atom and bond makeup of kinase drugs. The company's platform leverages multiple layers of kinase biology to design safer and more efficacious kinase therapeutics. Harmonic Discovery focus on therapeutics within the human kinome, a family of 500 proteins associated with diseases such as cancer, autoimmunity, and neurodegeneration.